AGO4: A Potential Drug Target and Biomarker (G192670)

Target Name: AGO4

NCBI ID: G192670

AGO4

AGO4: A Potential Drug Target and Biomarker

The Angiotensin-converting enzyme 4 (AGO4) is a protein that is expressed in various tissues throughout the body. It plays a crucial role in regulating various physiological processes, including blood pressure, inflammation, and fibrosis. GAG4 has also been implicated in the development and progression of various diseases, including cardiovascular disease, neurodegenerative disorders, and cancer. As a result, it has become an attractive target for drug development. In this article, we will discuss the potential drug target and biomarker of AGO4, as well as its current research status and potential therapeutic applications.

Potential Drug Target

AGO4 is a validated drug target, with several studies showing its potential as a therapeutic agent. One of the main advantages of AGO4 is its unique structure, which consists of a catalytic active site, a regulatory domain, and a catalytic domain. The catalytic active site is located in the center of the protein and is responsible for the conversion of substrate molecules to produce activating angiotensin II. The regulatory domain is located at the N-terminus of the protein and plays a role in regulating the activity of the catalytic domain. The catalytic domain is responsible for the production of the final product, which is a highly reactive and potent enzyme that can cause various physiological effects.

Several studies have shown that AGO4 can be a potential drug target by blocking its activity with small molecules, such as inhibitors. These inhibitors can prevent AGO4 from converting substrate molecules to activate angiotensin II, which can downregulate the activity of the enzyme and reduce the production of activating angiotensin II. This can lead to the inhibition of various physiological effects, including inflammation, fibrosis, and cancer progression.

Biomarker

AGO4 has also been shown to be a potential biomarker for various diseases. Its expression has been observed in various tissues, including blood vessels, heart, brain, and cancer. It has also been shown to be involved in the development and progression of various diseases, including cardiovascular disease, neurodegenerative disorders, and cancer. As a result, AGO4 has the potential to serve as a biomarker for these diseases and to aid in their diagnosis and treatment.

Current Research Status

Current research on AGO4 is focused on its potential drug target and biomarker applications. Several studies have shown that AGO4 can be inhibited by small molecules, including inhibitors that target the catalytic or regulatory domain. These inhibitors have been shown to block the activity of AGO4 and reduce the production of activating angiotensin II.

Another approach to studying AGO4 is its expression and localization in various tissues. Studies have shown that AGO4 is expressed in various tissues, including blood vessels, heart, brain, and cancer. It has also been shown to localize to the endoplasmic reticulum (ER), a protein retrieval system that transports proteins from the endoplasmic reticulum to the cytoplasm. This localization is important for the function of AGO4, as it allows it to interact with other proteins and to be targeted by small molecules.

Potential Therapeutic Applications

The potential therapeutic applications of AGO4 are vast and varied. As a drug target, AGO4 has the potential to treat a variety of diseases, including cardiovascular disease, neurodegenerative disorders, and cancer. By inhibiting its activity with small molecules, AGO4 can be used to treat these diseases and to improve the overall health and wellbeing of patients.

In addition to its potential therapeutic applications, AGO4 has the potential to serve as a biomarker for various diseases. Its expression and localization to the ER make it an attractive target for diagnostic tests and therapies that can aid in the diagnosis and treatment of these diseases.

Conclusion

AGO4 is a protein that has been shown to play a crucial role in various physiological processes

Protein Name: Argonaute RISC Component 4

Functions: Required for RNA-mediated gene silencing (RNAi). Binds to short RNAs such as microRNAs (miRNAs) and represses the translation of mRNAs which are complementary to them. Lacks endonuclease activity and does not appear to cleave target mRNAs. Also required for RNA-directed transcription and replication of the human hapatitis delta virus (HDV)

The "AGO4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AGO4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets